[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurocognitive-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurocognitive-disorders":731},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,32,0,25,[9,43,102,134,160,192,213,236,257,289,314,342,373,393,417,449,477,501,529,562,587,615,658,679,704],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100545475",false,"NCT06382389","Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial-","Efficacy of EMONO as an add-on Therapy to Conventional Antidepressants for the Treatment of Depressive Symptoms in Nursing-home Residents With Neurocognitive Disorders: a Randomized Controlled Trial","PROTO-EHPAD","Inclusion Criteria:\n\n* Men and women aged 60 and over living in nursing home\n* Diagnosis of major neurocognitive disorder according to DSM-V for at least 6 month\n* MMSE \\\u003C= 20\u002F30\n* NPI depression \\>= 4\u002F12\n* Patient, family and legal representive consent where applicable Person affiliated to a social security schem\n\nExclusion Criteria:\n\n* NPI agitation \\> 6\u002F12\n* Unstable somatic pathology (in particular unstable neurological or cardiological pathologies at risk of interfering with the diffusion of MEOPA) and any unexplained recent neurological abnormality.\n* Contraindications to the use of MEOPA\n* Patients who have already been treated with MEOPA in the 6 months prior to inclusion, for example for painful treatment\n* Sub-physiological plasma vitamin B12 or B9 concentration (below the lower limit of the laboratory value).\n* A person participating in a clinical drug study or in a period of exclusion from any clinical study due to previous participation\n* Personne participant à une étude clinique médicamenteuse ou en période d'exclusion de toute étude clinique du fait d'une précédente participation","ALL","60 Years",{"count":20,"type":21},96,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Depression in neurocognitive disorders (Alzheimers' disease and related disoders) is a highly prevalent condition, especially in nursing homes. While it is associated with significant distress, the current conventional antidepressants have shown only modest efficacy and exposed to potentially severe side effects.\n\nRecent evidence suggests that nitrous oxide (N2O) in its most commonly used packaging of EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide) has rapid antidepressant properties and a good safety profile. However, no study has investigating the antidepressant effect of EMONO in a population of depressed older adults with moderate to severe neurocognitive disorders in nursing homes.\n\nThe principal goal of the PROTO-EHPAD study is to compare the changes in depressive symptoms in such individuals in a randomized controlled trial with a follow up period of 8 weeks, with a dosage escalation procedure.",[27,28],"Depression","Neurocognitive Disorders",[30],"Nitrous Oxide","NOT_YET_RECRUITING","2026-06-16",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":21},"2026-09",{"date":39,"type":21},"2028-09",{"name":41,"class":42},"University Hospital, Tours","OTHER",{"id":44,"slug":4,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":70,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100496255","NCT05741853","Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia","Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia","Inclusion Criteria:\n\n* Meets diagnostic criteria for Primary Progressive Aphasia (PPA; Gorno-Tempini et al., 2011)\n* Bilingual in Spanish and Catalan or bilingual in Spanish and English\n* Different proficiency levels across languages are expected, any prior experience in both languages is acceptable\n* Intervention study: Score of 15 or higher on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of 10 or higher on the Mini-Mental State Examination\n\nExclusion Criteria:\n\n* Other central nervous system or medical diagnosis that can cause symptoms\n* Other psychiatric diagnosis that can cause symptoms\n* Significant, uncorrected visual or hearing impairment that would interfere with participation\n* Prominent initial non-speech-language impairments (cognitive, behavioral, motoric)\n* Intervention Study: Score of less than 15 on the Mini-Mental State Examination\n* Note that this project will also recruit individuals to participate in assessment only, for these individuals the following inclusion criteria applies: Score of less than 10 on the Mini-Mental State Examination",true,"40 Years",{"count":52,"type":21},60,[54],"NA","Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.\n\nThe overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how \"strong\" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.",[57,58,59,60,61,62,63,64,65,66,67,28,68,69],"Primary Progressive Aphasia","Dementia","Dementia, Frontotemporal","Alzheimer Disease","Neurodegenerative Diseases","Frontotemporal Lobar Degeneration","Apraxia, Motor","Dysarthria","Communication Disorders","Language Disorders","Speech Disorders","Aphasia","Bilingual Aphasia",[71,72,73,57,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90],"Dementia, ADRD","Bilingualism","Multilingualism","Bilingual Primary Progressive Aphasia","Cognitive Reserve","Language Decline","Bilingual Language Decline","Speech-Language Therapy","Bilingual Speech-Language Therapy","Spanish speakers","Spanish-Catalan Bilinguals","Spanish-English Bilinguals","Hispanic","Catalán","Catalan","Spanish","Castellano","Speech Therapy","Latino","Cognition","RECRUITING","2026-06-08",{"date":94,"type":35},"2026-06-10",{"date":96,"type":35},"2023-05-01",{"date":98,"type":21},"2027-11-30",{"name":100,"class":42},"Stephanie Grasso",3,{"id":103,"slug":4,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":4},"100639710","NCT07626567","Prospective Neuropsychological Evaluation of the Implementation of a Heart Valve Unit (HVU-NEURO)","HVU-NEURO","Inclusion Criteria:\n\n* Severe aortic valve stenosis\n* Indication for transcatheter valve therapy according to current guideline recommendations and\u002For Heart-Team consensus\n* Sufficient German language proficiency, as study-related tests, questionnaires, and instructions are administered in German\n* Age ≥18 years\n* Willingness to participate voluntarily with written informed consent\n\nExclusion Criteria:\n\n* Known pregnancy at the time of study inclusion\n* Life expectancy \\\u003C1 year due to non-cardiac disease\n* Pre-interventional psychiatric and neurological disorders (known and diagnosed dementia, depression, history of stroke or transient ischemic attack \\[TIA\\], migraine, epilepsy) with acute symptoms that may interfere with data collection","18 Years",{"count":110,"type":21},500,"OBSERVATIONAL","Transcatheter aortic valve implantation (TAVI) is an established treatment for severe aortic stenosis. Despite improved procedural outcomes, neurocognitive complications such as postoperative delirium (POD) and postoperative cognitive decline (POCD) remain clinically relevant.\n\nHeart Valve Units (HVU) are specialized interdisciplinary care structures designed to improve treatment pathways and healthcare quality. However, their impact on neuropsychological outcomes has not been sufficiently investigated.\n\nHVU-NEURO is a prospective observational cohort study evaluating neuropsychological outcomes before and after implementation of an HVU. Approximately 500 patients undergoing transcatheter valve therapy will be included.\n\nNeurocognitive function will be assessed before intervention, at hospital discharge, and three months after intervention. POD will be assessed using the Intensive Care Delirium Screening Checklist (ICDSC). The primary objective is to evaluate the effect of HVU implementation on postoperative cognitive decline at discharge from acute hospital care.",[114,115,116,28],"Aortic Valve Stenosis","Postoperative Cognitive Dysfunction (POCD)","Delirium - Postoperative",[118,119,120,121,122,123,124],"TAVI","HVU","Postoperative Cognitive Decline","Postoperative Delirium","Neuropsychology","Transcatheter Aortic Valve Implantation","Intensive Care Delirium Screening Checklist","2026-05-29",{"date":127,"type":35},"2026-06-04",{"date":129,"type":21},"2026-05-25",{"date":131,"type":21},"2028-02",{"name":133,"class":42},"Heart and Brain Research Group, Germany",{"id":135,"slug":4,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":111,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100608703","NCT07205003","Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders","Evaluation of the Link Between Carotid Arterial Wall Viscosity and Major Neurocognitive Disorders of Vascular Origin or Linked to Alzheimer's Disease","VISCOG","Inclusion Criteria:\n\n* Age over 70\n* Memory consultation consultant (neurology or geriatrics)\n* Brain MRI less than one year old or planned as part of the cognitive assessment performed.\n* Patient diagnosed with Alzheimer's disease according to DSM-5 criteria or vascular dementia according to DSM-5 criteria, or presenting a memory complaint without evidence of a dementia-related condition.\n* No objection from the patient or their caregiver.\n* Patient covered by a health insurance plan\n\nExclusion Criteria:\n\n* Known unilateral or bilateral carotid stenosis or history of carotid surgery\n* Permanent CA\u002FAF\n* Patient presenting with confusion\n* Known psychiatric illness (severe depression, psychosis, etc.)\n* Non-vascular, non-Alzheimer's dementia (e.g., Lewy Body Dementia, Parkinsonian Dementia, Progressive Supranuclear Palsy)\n* Refusal to participate\n* MMS less than or equal to 10\n* Contraindication to performing an MRI\n* Any acute decompensated pathology\n* Patient under guardianship or curatorship","70 Years",{"count":143,"type":21},140,"1 Day","The mechanical behavior of conductance arteries is viscoelastic. While the elastic component has been extensively studied, the viscous component has often been neglected for methodological reasons and also because it was considered weak.\n\nUnlike a purely elastic solid, which exhibits instantaneous deformation\u002Frelaxation upon application\u002Fdiscontinuation of a force, a viscoelastic solid is characterized, from a mechanical point of view, by a delay between the application or discontinuation of the force and deformation. Thus, at the arterial level, the elasticity of the arterial wall allows the internal diameter to increase proportionally to the blood pressure during systole. The viscous component will induce a delay in diameter restoration, resulting in a larger diameter at each pressure level during the diastolic phase compared to the systolic phase. This results in a shift between the systolic and diastolic curves of the pressure-diameter relationship, creating a hysteresis loop. From a thermodynamic point of view, while a purely elastic material fully restores the energy stored during the loading phase, viscoelastic arteries will incompletely restore this energy. Thus, the surface of the hysteresis loop reflects the energy dissipated during each cardiac cycle (WV), and the area under the loading phase curve represents the energy stored by the arterial wall (WE) during the latter. Thus, arterial wall viscosity (APV) can be expressed either as the absolute value of WV or as a function of the stored energy (WV\u002FWE). Physiologically, this energy loss is low. Its increase could be accompanied by excessive energy dissipation, leading to increased cardiac work and cardio-circulatory decoupling. Conversely, low parietal viscosity could lead to damage to peripheral organs by excessive transmission of pulsatile energy to the periphery due to lack of damping.",[28,147],"Alzheimer's Disease",[149],"carotid arterial wall viscosity","2026-05-21",{"date":152,"type":35},"2026-05-22",{"date":154,"type":35},"2022-02-15",{"date":156,"type":21},"2028-05-15",{"name":158,"class":42},"University Hospital, Rouen",1,{"id":161,"slug":4,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":170,"briefSummary":171,"conditions":172,"keywords":177,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":159},"100633442","NCT07526740","Brain Stimulation and Cognitive Training for MCI","Combining Brain Stimulation With Computerized Cognitive Training for MCI","RISE pilot","Inclusion Criteria:\n\n1. Age 60-85 (inclusive).\n2. English as a first\u002Fprimary language.\n3. Adequate sensorimotor function and verbal expressive abilities to complete all assessments.\n4. Must have a co-participant (e.g. spouse, adult child or relative, sibling, cohabitator, friend, caregiver) who has at least weekly in-person contact with the participant and is willing to participate in the study as a collateral informant.\n5. Meets the following requirements for current and prior medications and treatments:\n\n   1. Is on fixed pharmacotherapy (i.e. stable dose of medication\u002Fs) for ≥ 4 weeks before enrollment. This includes, but is not limited to, cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants.\n   2. Anti-amyloid monoclonal antibody therapy for AD\u002FMCI:\n\n      * Prior treatment is permitted if last infusion occurred ≥ 8 weeks before enrollment.\n      * Current treatment is permitted if the dose has been stable for ≥ 12 weeks before enrollment, with no planned dose change during study participation.\n   3. Prior TMS treatment is permitted if the last stimulation session was ≥ 24 weeks before enrollment.\n6. Documented diagnosis of MCI per NIA-AA criteria or Mild Neurocognitive Disorder per DSM-5 criteria by a healthcare provider within the past year, with a presumed etiology of possible or probable AD 7. Met actuarial neuropsychological criteria for MCI43 within the past year (i.e. ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using appropriate demographically-corrected norms).\n\nExclusion Criteria:\n\n1. Telephone Interview for Cognitive Status (TICS) score of ≤ 22 suggestive of dementia.\n2. Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5).\n3. Daily\u002Fweekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review.\n4. History of significant or unstable condition\u002Fs or treatments for these condition\u002Fs that may impact cognition (as determined by the study investigators) such as significant cardiac (e.g. heart failure), infectious (e.g. HIV, urinary tract infection), or metabolic disease (e.g. labile diabetes), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), severe mental illness (e.g., bipolar disorder, psychoses), alcohol or substance use disorder, developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury, seizures).\n5. Plan to initiate treatment for AD\u002FMCI with monoclonal antibody therapy during study participation.\n6. For those currently receiving monoclonal antibody therapy, documented history of clinically significant amyloid-related imaging abnormalities (ARIA) in their medical record.\n7. Current use of any implanted brain stimulation device.\n8. Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days that may impact cognition or mood.\n9. MRI contraindications (e.g., ferromagnetic implants, claustrophobia).\n10. Unable or unwilling to engage in BrainHQ activities.\n11. TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking medications that have short half-lives) or no identifiable motor threshold.","85 Years",{"count":169,"type":21},50,[54],"This is a randomized clinical trial of a treatment that combines non-invasive brain stimulation with computerized cognitive training (CCT) for people with mild cognitive impairment (MCI). The form of brain stimulation used in this study is accelerated intermittent theta burst stimulation (iTBS). All participants receive the same amount of iTBS and are randomly assigned to engage in one of two types of CCT. The goals of the study are to see if this combined treatment is feasible and acceptable to people with MCI and whether combined iTBS and CCT improves memory, thinking skills, mood, and daily function.",[173,174,28,175,176],"Mild Cognitive Impairment (MCI)","Mild Neurocognitive Disorder","Cognitive Dysfunction","Cognition Disorders",[178,179,180,181,182,183],"Aging","Alzheimers","Memory Loss","Mild Cognitive Impairment","Transcranial Magnetic Stimulation","cognitive training","2026-05-20",{"date":152,"type":35},{"date":187,"type":35},"2026-03-16",{"date":189,"type":21},"2030-05-31",{"name":191,"class":42},"Medical University of South Carolina",{"id":193,"slug":4,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":159},"100478031","NCT05504681","Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic","Inclusion Criteria:\n\n1. All adult (18+) patients with central nervous system (CNS) tumors, both primary brain malignancies and brain metastases, treated with radiotherapy (partial brain, stereotactic radiosurgery, stereotactic fractionated radiotherapy, or whole-brain radiotherapy), surgery, and\u002For antineoplastic therapy and followed thereafter at Miami Cancer Institute (MCI)\n2. Life expectancy ≥ 6 months\n3. Willingness to participate in ongoing registration study\n\nExclusion Criteria:\n\n1. Patients receiving radiotherapy to the brain for functional disease (arteriovenous malformations, trigeminal neuralgia, essential tremors, etc.)\n2. Pediatric patients (\\\u003C18 years old), pregnant women, and prisoners.",{"count":198,"type":21},200,"This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.",[28],[202,203],"Neurocognitive","Brainlab Cognition app","2026-05-18",{"date":206,"type":35},"2026-05-19",{"date":208,"type":35},"2021-11-30",{"date":210,"type":21},"2032-04",{"name":212,"class":42},"Baptist Health South Florida",{"id":214,"slug":4,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":49,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":159},"100490628","NCT05668598","Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics","Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics: an Adaptation of the Memory Test With Self-Initiated Items (MAI)","ECOTESTGER","Inclusion Criteria:\n\n* Male or female ≥ 70 ans\n* Person have good locomotion, move independently\n* Personne agree to participate\n\nGroupe 1 : 17≤MMSE≤24 (GRECO) Diagnosis of neurodegenerative diseases (major neurocognitive disorders: Alzheimer, mixed dementia, lobar frontotemporal degeneration, vascular dementia).\n\nGroupe 2 : MMSE ≥ à 25 (GRECO) Without neurodegenerative disease\n\nExclusion Criteria:\n\n* Person with legal protective measures\n* Person deprived of liberty\n* Mental retardation or MMSE≤ 16\n* Understanding verbal disorders\n* Visual major disturbances\n* Person with disease causing increased fatigue\n* Person with psychiatric pathology excepted anxiety disorder or depression with mild episodes.\n* Person not covered by French national health insurance",{"count":52,"type":21},[54],"In this study the participants can be recruited via scheduled consultation and external institutions (associations, senior club..). Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.\n\nStudy test is ecological MAI. This test are assigned in two groups (with or without neurocognitive disorders).",[224,28],"Memory Disorders",[226],"GERIATRICS","2026-05-05",{"date":229,"type":35},"2026-05-08",{"date":231,"type":35},"2023-03-08",{"date":233,"type":21},"2028-03-09",{"name":235,"class":42},"Centre Hospitalier de Lens",{"id":237,"slug":4,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":159},"100449182","NCT05129150","Cognitive Disorders and Brain Pulse","COG-PULCE","Inclusion Criteria:\n\n* Patient benefiting from a day hospital at the MRRC of the CHU of Tours for assessment of cognitive functions\n\nExclusion Criteria:\n\n* Refusal of TPI ultrasound examination\n* Patients who opposed to data processing\n* Patients under judicial protection",{"count":243,"type":21},300,"Following an initial consultation with a memory, resources and research centre (MRRC) doctor, a day hospital may be prescribed to carry out an assessment of cognitive disorders. Patients are then usually followed up in consultation at least once a year, in the framework of a new day hospital and\u002For consultations with a MRRC doctor.",[28],[247,248],"Brain pulse","ultrasound","2026-04-29",{"date":251,"type":35},"2026-05-06",{"date":253,"type":35},"2022-03-31",{"date":255,"type":21},"2032-03",{"name":41,"class":42},{"id":258,"slug":4,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":167,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":274,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":288},"100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.",{"count":265,"type":21},180,[54],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[269,58,270,271,272,61,28,273],"Alzheimer's Disease","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Mental Disorder",[275,276,277,58],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":280,"type":35},"2026-04-23",{"date":282,"type":35},"2023-05-15",{"date":284,"type":21},"2027-06-30",{"name":286,"class":287},"Advanced Technology & Communications","INDUSTRY",11,{"id":290,"slug":4,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100616779","NCT07310043","Creatine and Perioperative Brain Health","Creatine Intervention in Older Adults to Improve Perioperative Brain Health","CREATE","Inclusion Criteria:\n\n* Patients scheduled for elective surgery under general anesthesia\n\nExclusion Criteria:\n\n* History of creatine deficiency disorders\n* Severe neurologic or psychiatric diseases\n* History of stroke or head trauma\n* Obesity (BMI ≥ 30 kg.m-²), kidney or liver disease","75 Years",{"count":298,"type":21},80,[54],"The goal of this study is to understand the effects of oral creatine supplementation in the perioperative period. Creatine is commonly used to enhance athletic performance, but it can also have positive effects on the brain. Since surgery can lead to alterations in thinking, memory, and attention patterns in some patients, we will assess whether creatine can be protective against these changes in older adults undergoing surgery.",[28,121],[303,304,305],"Perioperative Brain Health","Creatine","Perioperative Neurocognitive Disorders","2026-04-19",{"date":278,"type":35},{"date":309,"type":21},"2026-07-01",{"date":311,"type":21},"2028-06-30",{"name":313,"class":42},"Massachusetts General Hospital",{"id":315,"slug":4,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":159},"100482374","NCT05561205","rTMS for Apathy Clinical Trial","Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)","REACT","Inclusion Criteria:\n\n* mild or major neurocognitive disorder OR mild behavioural impairment\n* Apathy for at least 4 weeks\n* Stable dose of medication (\\>4 weeks) that may affect cognition or behaviour\n* Care partner who spends at least 10 hours a week with the subject\n\nExclusion Criteria:\n\n* Current major depressive episode\n* Agitation, delusions, hallucination\n* Medical contraindications to rTMS\n* Currently taking an amphetamine product\n* Central nervous system abnormalities, Tourette's syndrome, or motor tics\n* Current participation in another clinical trial",{"count":322,"type":21},10,[54],"Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiving methylphenidate and individuals not receiving medication for apathy.",[60,326,58,327,181,28],"Apathy in Dementia","Mild Behavioural Impairment",[329,330,331,332],"Apathy","Alzheimer's disease","Neurocognitive disorder","Mild behavioural impairment","2026-04-10",{"date":335,"type":35},"2026-04-13",{"date":337,"type":35},"2023-02-09",{"date":339,"type":21},"2026-12-01",{"name":341,"class":42},"Sunnybrook Health Sciences Centre",{"id":343,"slug":4,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":360,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":372},"100510689","NCT05929703","Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders","Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders (ENHANCE)","ENHANCE","Inclusion Criteria:\n\n* Provision of informed consent\n* At least 70 years of age\n* Anticipated length of hospital stay at least 72 hours\n* Family member or care partner available to be on-site in the hospital\n* At least one delirium risk factor (e.g., cognitive or functional impairment, dehydration, vision or hearing impairment)\n* Evaluable cognitive function at baseline (i.e., ability to complete baseline cognitive function assessment)\n\nExclusion Criteria:\n\n* Delirium on admission\n* Unable to communicate verbally (e.g., coma, mechanical ventilation)\n* Unable to participate fully in interventions (e.g., terminal condition, advanced dementia)\n* Staff safety concerns (e.g., violent behavior)\n* Cardiac or intracranial surgery (due to competing causes of delirium)",{"count":350,"type":21},1900,[54],"The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following:\n\n1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity.\n2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes.\n3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.",[354,28,181,60,178,355,356,357,358,359],"Delirium","Family Support","Family Members","Caregiver Burden","Implementation Science","Patient Satisfaction",[354,361,362,358],"Clinical Trial","Comparative Effectiveness Research","2026-03-20",{"date":365,"type":35},"2026-03-24",{"date":367,"type":35},"2023-12-04",{"date":369,"type":21},"2027-08",{"name":371,"class":42},"University of Michigan",7,{"id":374,"slug":4,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":49,"sex":17,"minAge":380,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":322},"100497232","NCT05754567","CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes","CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes: A Follow up Study of the CONCEPTT Randomized Control Trial","CONCEPTTKids","Inclusion Criteria:\n\n* Children of women who participated in the CONCEPTT trial at selected recruiting sites\n\nExclusion Criteria:\n\n* NA","6 Years",{"count":382,"type":21},225,"Neurodevelopmental Outcomes among Offspring of women with Type 1 Diabetes: A Follow up Study of the CONCEPTT Randomized Control Trial (CONCEPTT Kids International). An international, multicentre prospective cohort study of child and mother pairs. The potential number of recruits is 225 and the main inclusion criteria is child's mother who participated in the CONCEPTT Trial.",[28],"2026-03-18",{"date":363,"type":35},{"date":388,"type":35},"2023-09-07",{"date":390,"type":21},"2027-01",{"name":392,"class":42},"University of Manitoba",{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":17,"minAge":400,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":159},"100511776","NCT05943834","Early Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis (PLATA)","Early Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis","PLATA","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Diagnosis relevant biomarker and neuropsychological data already available\n* Cognitively healthy to very mild dementia (CDR score max. 0.5)\n* Sufficient knowledge of the study language to understand study information, non opposition form,and questionnaires\n* Expression of non opposition\n\nExclusion Criteria:\n\n* Hearing problems\n* Patient protected by law, under guardianship or curator ship, or not able to participate in a clinical study according to the article L.1121-16 of the French Public Health Code","50 Years","100 Years",{"count":403,"type":21},100,"PLATA aims to develop an algorithm to identify vocal biomarkers of Alzheimer's dementia.\n\nUsing data collected as part of routine care, speech patterns will be compared to known biomarkers of Alzheimer's disease, such as amyloid 1-42 and p-Tau in CSF (cerebrospinal fluid).\n\nIf biomarkers of speech can be identified in Alzheimer's disease, it is possible that patients and research participants will no longer need to undergo need to undergo the intensive and invasive baseline biomarker methods currently used, such as lumbar punctures and PET scans.",[28],[330,407],"Mood disorder","2026-03-17",{"date":410,"type":35},"2026-03-19",{"date":412,"type":35},"2023-07-13",{"date":414,"type":21},"2027-10-10",{"name":416,"class":42},"Centre Hospitalier Universitaire de Nice",{"id":418,"slug":4,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":296,"enrollmentInfo":424,"targetDuration":144,"studyType":111,"phases":4,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":159},"100625082","NCT07418008","The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)","Development and Psychometric Validation of The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)","LiCCoS","Inclusion Criteria:\n\n* Age 18-75 years.\n* Documented clinical diagnosis of liver cirrhosis based on imaging, histology, or validated clinical criteria.\n* Able to read and understand the language of the cognitive tests.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>75 years\n* Known case of Overt Hepatic Encephalopathy defined as Grade II or higher on the West Haven criteria \\[25\\].\n* Use of central nervous system depressants, anticholinergics, or psychotropics initiated or changed within the past 4 weeks.\n* Known case of Severe uncorrected visual or hearing impairment limiting ability to complete cognitive testing.\n* Known case of Any neurological and psychological disorders, substance use disorder and sleep disorders.\n* Known case of Severe systemic illness (e.g., end-stage renal disease, decompensated heart failure) that may independently impair cognition or limit participation.",{"count":425,"type":21},230,"The goal of this observational study is to develop and test a new questionnaire called the Liver Cirrhosis Cognitive Decline Scale (LiCCoS) for adults with liver cirrhosis. This questionnaire is designed to help identify problems with thinking and daily mental functioning that are common in people with liver cirrhosis but are often missed during routine care.\n\nPeople with liver cirrhosis may experience problems such as forgetfulness, slowed thinking, trouble paying attention, or difficulty planning everyday tasks. These problems can affect daily life, safety, and treatment adherence. Existing cognitive tests often require special training or equipment and may not fully reflect how people experience these difficulties in daily life. This study aims to create a simple, patient-reported tool that captures these concerns in an easy and practical way.\n\nThe main questions this study aims to answer are:\n\n1. Can the LiCCoS questionnaire reliably measure cognitive difficulties in adults with liver cirrhosis?\n2. Does the questionnaire correctly reflect differences in cognitive function across levels of liver disease severity?\n3. Do LiCCoS scores relate to results from commonly used cognitive screening tests?\n\nParticipants will be adults aged 18 to 75 years who have a confirmed diagnosis of liver cirrhosis and are attending outpatient clinics. Participation is voluntary.\n\nParticipants will:\n\nProvide basic background information, such as age and medical history\n\nComplete the LiCCoS questionnaire about their thinking and daily mental functioning\n\nComplete standard cognitive screening tests commonly used in clinical care\n\nThis study does not involve any treatment or change in medical care. The information collected will be used only for research purposes. The results are expected to help develop a reliable and easy-to-use tool that can support early recognition of cognitive difficulties in people with liver cirrhosis and improve communication between participants and health care providers.",[428,175,429,28],"Liver Cirrhosis","Hepatic Encephalopathy",[422,431,432,433,434,435,436,437,438,439],"Liver cirrhosis","Cognitive impairment","Cognitive dysfunction","Hepatic encephalopathy","Patient-reported outcome measure","Psychometric validation","Scale development","Cognitive assessment","Chronic liver disease","2026-02-10",{"date":442,"type":35},"2026-02-18",{"date":444,"type":35},"2025-12-15",{"date":446,"type":21},"2026-11-30",{"name":448,"class":42},"University of Malaya",{"id":450,"slug":4,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":476},"100615619","NCT07294963","Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease","Impact of Lifestyle Interventions on Cognitive Decline in NAFLD: A Randomized Controlled Trial of Liver Fibrosis, Hormonal Imbalance, and Inflammatory Markers","Inclusion Criteria:\n\n* Age 18 to 42 years.\n* Diagnosed with fatty liver (NAFLD) via imaging (e.g., ultrasound).\n* Liver fibrosis assessed and staged via FibroScan and the FIB-4 index.\n* Literate (to consent and complete cognitive assessments\u002Fquestionnaires).\n\nExclusion Criteria:\n\n* History of alcohol intake \\>20g\u002Fday.\n* Chronic viral hepatitis B or C.\n* Major neuropsychiatric illnesses.\n* Pregnancy or breastfeeding.\n* Chronic illnesses including Diabetes Mellitus and thyroid dysfunction.","42 Years",{"count":457,"type":21},45,[54],"This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD). We are enrolling 45 participants, aged 18-42, who will be randomly assigned to one of three groups for six months: one receiving general health advice, a second following a supervised Mediterranean diet plan, and a third combining the same diet with a regular walking program. The main goal is to see if these diet and exercise interventions can lead to better scores on memory and reasoning tests, reduce liver stiffness measured by a painless scan (FibroScan), and improve related blood markers of inflammation and hormone balance.",[461,28],"Non-Alcoholic Fatty Liver Disease",[463,464,465,466,461],"Hepatocerebral Syndrome","Metabolic dysfunction-Associated SteatoHepatitis","Cognitive Decline","Liver Fibrosis","2025-12-08",{"date":469,"type":35},"2025-12-19",{"date":471,"type":35},"2025-10-01",{"date":473,"type":21},"2026-06-15",{"name":475,"class":42},"Khyber Medical University Peshawar",2,{"id":478,"slug":4,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":22,"phases":486,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":159},"100565171","NCT06638710","Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and Refusing Care.","Efficacy and Safety of Oral Midazolam for the Delivery of Care in Elderly Patient With Moderate to Severe Neurocognitive Disorders and Refusing Care","MIRAGE","Inclusion Criteria:\n\n* Patient hospitalized (for a minimum estimated duration of 21 days) in a geriatric department in Medical Care and Rehabilitation, Cognitive-Behavioral Unit, or housed in a Reinforced Housing Unit, in a Long-Term Care Unit, or in a Psycho-Geriatric Unit.\n* Moderate to severe cognitive impairment, defined by a MMSE (Mini Mental State Examination) score \\<15. If not feasible at inclusion, MMSE score \\<15 less than 1 year old.\n* Patient opposed to care, presenting at least two episodes of opposition to care (meals excluded) for which other non-medication alternatives have failed. These refusals of care are defined by a \\"resistance to care\\" score ≥3 on the Pittsburgh scale, over the last week. In practice, the resistance to care of patients is noted in the medical record following a weekly multidisciplinary decision.\n\nThe targeted cares:\n\nEssential nursing care (indispensable, mandatory, and prescribed) Bathing and changing made essential by obvious lack of hygiene after evaluation Bedtime installation (e.g., with the SECURIDRAP® device) technical care: blood tests, wound care, dressing changes, insertion of urinary or nasogastric tubes; administration of medication by parenteral route\n\n* Person affiliated with social security or beneficiary of such a scheme\n* Informed, written, and signed consent by the patient or their legal representative (for adults under legal protection and unable to express their consent)\n\nExclusion Criteria:\n\n* Patient who has received midazolam treatment in the week before inclusion\n* Patient with contraindications to midazolam:\n\nsevere Myasthenia Severe respiratory failure requiring continuous oxygen therapy Severe liver failure: PT \\<50% Severe sleep apnea syndrome not treated with a device Severe renal failure: Cockcroft \\<20mL\u002Fmin Severe heart failure in a state of decompensation History of alcoholism or drug addiction\n\n* Known hypersensitivity to the active substance, benzodiazepines, or any of the excipients\n* Patient being treated concurrently with:\n\nCYP3A4 enzyme inhibitors CYP3A4 enzyme inducers\n\n* Weight \\<50 kg and \\>100 kg\n* Gastrointestinal pathology that may limit or prevent the absorption of midazolam\n* Identification of anxiety, defined by item E of the NPI (neuropsychiatric inventory) by an evaluation \\>2 in frequency and severity according to HAS recommendations.\n* Identification of pain, defined by the Algoplus scale by an evaluation ≥2\n* Identification of ideational disorders, defined by item E of the Cornell scale: E\\>0\n* Subject in the exclusion period of another clinical trial\n* Subject deprived of liberty by an administrative or judicial decision.",{"count":485,"type":21},30,[24],"The purpose of this study is to assess the effectiveness of oral midazolam on the delivery of care in elderly patients with moderat to severe neurocognitive disorders and opposing care.",[28],[490,491,492],"elderly","midazolam","care","2025-12-05",{"date":444,"type":35},{"date":496,"type":35},"2025-07-08",{"date":498,"type":21},"2026-11-01",{"name":500,"class":42},"University Hospital, Grenoble",{"id":502,"slug":4,"hasResults":11,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":11,"sex":17,"minAge":508,"maxAge":167,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":516,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":476},"100581676","NCT06853405","Nutrition-based Interventions to Prevent Cognitive Decline","NUTRIMIND: Nutrition-based Interventions to Prevent Cognitive Decline","NUTRIMIND","Inclusion Criteria:\n\n* Aged from 55 to 85 years old;\n* At least 4 years in the regular school system;\n* Higher individual risk for dementia defined as a score ≥6 points on the Cardiovascular Risk Factors, Aging and Dementia Dementia Risk Score (CAIDE).\n\nExclusion Criteria:\n\n* Montreal Cognitive Assessment (MoCA) score lower than the validated cutoff points defined as 2 standard deviations below the normative reference value for the corresponding age and education in the Portuguese population;\n* Having a medical condition limiting the participation in the intervention (e.g., blindness, amputation…);\n* Lack of autonomy in daily activities;\n* Diagnosis of dementia or major incapacity.","55 Years",{"count":510,"type":21},120,[54],"This study intends to evaluate the feasibility and the effectiveness of an innovative and integrated nutrition-based intervention addressing key modifiable risk factors for dementia while meeting participants' preferences for nutrition-related sessions. The intervention will include lifestyle group sessions regarding nutrition education and physical activity, individualized cognitive training at home, as well as clinical nutrition consultations.",[175,514,224,515,28],"Cognition Disorder","Cognitive Impairment",[517,58,175,518,519,520],"Healthy Aging","Diet, Food and Nutrition","Diet, Mediterranean","Randomized Controlled Trial","2025-11-27",{"date":493,"type":35},{"date":524,"type":35},"2025-01-27",{"date":526,"type":21},"2026-08",{"name":528,"class":42},"Instituto de Saude Publica da Universidade do Porto",{"id":530,"slug":4,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":561},"100384702","NCT04289142","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial","CODEX","Inclusion Criteria:\n\n* Planned CABG (+\u002F- valve, including off-pump) or valve replacement via sternotomy\u002Fthoracotomy, with initial recovery in the Cardiovascular Intensive Care Unit (CVICU)\n* Age ≥60\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Pre-operative major cognitive dysfunction (CogState Brief Battery score \\\u003C 80) at screening\n* Aortic arch replacement\u002Fre-implantation (surgery requiring hypothermic circulatory arrest, e.g. Bentall procedure)\n* Allergy\u002Fcontraindication to dexmedetomidine (untreated 2nd degree type 2 or 3rd degree heart block (pacemaker), cirrhosis, HR \\\u003C 50 , grade 4 LV, renal failure or on renal replacement therapy)\n* Unlikely to comply with study assessments (e.g. no fixed address, cannot complete cognitive tests at the 3, 6, and 12 month time points)",{"count":537,"type":21},2400,[539],"PHASE4","Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.",[354,175,514,28,542,543,544,545,272,546,547,548,549,550,551,552,553],"Mental Disorders","Confusion","Neurobehavioral Manifestations","Neurologic Manifestations","Signs and Symptoms","Dexmedetomidine","Hypnotics and Sedatives","Central Nervous System Depressants","Physiological Effects of Drugs","Analgesics, Non-Narcotic","Analgesics","Molecular Mechanisms of Pharmacological Action",{"date":555,"type":35},"2025-12-01",{"date":557,"type":35},"2019-12-01",{"date":559,"type":21},"2029-03",{"name":341,"class":42},8,{"id":563,"slug":4,"hasResults":11,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":586},"100596633","NCT07048002","Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery","Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)","INSPIRE","Inclusion criteria:\n\n* Male or female adult patients aged 60 years or older\n* Receiving elective cardiovascular surgery with cardiopulmonary bypass\n* Written Informed consent provided\n\nExclusion criteria:\n\n* Contraindication to MRI scanning\n* Not suitable for receiving interventions to achieve NeuroFirst target bundle\n* Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments\n* Breastfeeding or pregnancy\n* Terminal illness with a life expectancy of less than 3 months\n* Mental or legal disability\n* current enrollment in other interventional study",{"count":570,"type":21},912,[54],"the purpose of the study is to investigate whether a combined anesthetic targets bundle, known as the NeuroFirst strategy, focused on neurological protection, can reduce the incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) in patients undergoing cardiac surgery. Additionally, the trial will assess the safety of this strategy.\n\nThe NeuroFirst target bundle incorporates multiple parameters, including mean arterial pressure (MAP), bispectral index (BIS), regional cerebral oxygen saturation (rSO2), and arterial inflow temperature during cardiopulmonary bypass.\n\nThe primary question this study seeks to answer is: Does the NeuroFirst strategy reduce the incidence of SBI and PND in cardiac surgery?\n\nTo address this, researchers will compare the NeuroFirst strategy with routine institutional practices based on published guidelines. Participants will be randomly assigned to either the NeuroFirst group or the routine care group. All participants will undergo magnetic resonance imaging (MRI), be assessed using the Confusion Assessment Method (CAM) and the Montreal Cognitive Assessment (MoCA), and be followed for up to one year postoperatively.",[574,28,575,576],"Silent Brain Infarction","Cardiac Surgery","Neuroprotective","2025-11-19",{"date":579,"type":35},"2025-11-24",{"date":581,"type":35},"2025-07-06",{"date":583,"type":21},"2028-10-31",{"name":585,"class":42},"Chinese Academy of Medical Sciences, Fuwai Hospital",5,{"id":588,"slug":4,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":597,"conditions":598,"keywords":601,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":159},"100458152","NCT05245903","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside","Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia","Emerald-NRAD","Inclusion Criteria:\n\n* Ability of the participant and\u002For his\u002Fher legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information.\n* Ability to speak and read fluently in English\n* 18-89 years old (inclusive)\n* Normal or corrected to normal hearing and vision\n* Meet clinical diagnostic criteria for MCI or Mild AD, according to the criteria outlined above\n* Study partner available for duration of trial participation\n* At least one copy of the APOE ε4 allele\n* An aggregate risk score \\> 4 according to the risk analysis method developed by Sabbagh et al. (2017)\n* For individuals who are taking niacin (or a vitamin supplement with niacin) of \\>200mg, the completion of a two-week wash-out period\n\nExclusion Criteria:\n\n* Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician\n* Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician\n* Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician\n* Diagnosis of a mitochondrial disorder\n* Any MRI safety contraindications\n* History of drug hypersensitivity or intolerance to NR\n* Transient ischemic attack or stroke within 1 year prior to screening\n* History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen\n* History of head injury rated as moderate or worse, per DSM-5 criteria\n* History of seizure within prior 10 years\n* Current use of medication with known adverse effects on cognition (benzodiazepines, barbiturates, opiate analgesics, first generation antipsychotic medication, anticholinergics, sedating antihistamines, tricyclic anti-depressants)\n* Change in dose of any psychiatric medications within 4 weeks of screening visit\n* Prior use of L-DOPA, any anti-Parkinsonian medication, or prior treatment with anti-amyloid immunotherapy\n* Current use of putative mitochondrial enhancers or antioxidants (e.g. carnitine, creatine, Co-Q10, N-acetyl cysteine, pramipexole)\n* Initiation of treatment or change in dosing of acetylcholinesterase inhibitors (AChEIs) and memantine within 4 weeks of screening\n* Prior use of prescription narcotics 4 weeks before screening\n* Female subjects who are pregnant or breastfeeding\n* The current use of niacin (or a vitamin supplement with niacin) \\>200mg within the last two weeks prior to study visit","89 Years",{"count":596,"type":21},40,"This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.",[60,599,58,515,181,61,28,600,175,273],"Dementia Alzheimers","Neurocognitive Dysfunction",[602,603,604,181,605],"Passive sensing","Digital phenotyping","Alzheimer's Dementia","Digital biomarker","2025-11-04",{"date":608,"type":35},"2025-11-06",{"date":610,"type":35},"2022-05-31",{"date":612,"type":21},"2026-05-31",{"name":614,"class":42},"Mclean Hospital",{"id":616,"slug":4,"hasResults":11,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":49,"sex":17,"minAge":508,"maxAge":622,"enrollmentInfo":623,"targetDuration":625,"studyType":111,"phases":4,"briefSummary":626,"conditions":627,"keywords":635,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":159},"100464026","NCT05322343","Biobank and Brain Health in Bordeaux.","Biobank and Brain Health in Bordeaux. A Population-based Cohort to Study the Biology of Brain and Cognitive Aging in Young Seniors","B-cube","Inclusion Criteria:\n\nFor the main study:\n\n1. live in Bordeaux metropolitan area,\n2. be between 55 and 80 years old (included),\n3. selected in terms of socioeconomic level, according to a sampling strategy by age groups and income categories representative of the general population between 55 and 80 years of age\n4. be affiliated with the social security system,\n5. agree to take a blood sample for the biobank.\n\nFor the MRI sub-study: be between 55 and 75 years old (included). Inclusion criteria for the immune response substudy: be 70 years of age or older or participate in the MRI study; agree to take a supplemental blood sample for this substudy.\n\nExclusion Criteria:\n\nFor the main study: persons under guardianship (or more generally under protection), unable to give consent to participate.\n\nFor the MRI sub-study: have a contraindication to MRI examination (pacemaker, a valve prosthesis or any other internal electrical\u002Fmagnetic device; history of neurosurgery or aneurysm; claustrophobia; presence of metal fragments in the eyes, brain or spinal cord).","80 Years",{"count":624,"type":21},2050,"12 Months","B cube is a new generation cohort to study the determinants and natural history of brain aging, using molecular epidemiology, in a representative sample (N=2000) of the general population from the age of 55 (the approximate age of onset of the first cognitive disorders and a target population particularly receptive to prevention messages). Special interest will be given to nutrition, a promising environmental exposure for prevention.",[628,178,629,630,631,542,28,90,270,58,60,632,633,27,634],"Brain","Cognitive Aging","Immunosenescence","Mental Processes","Mental Health","Behavioral Symptoms","Anxiety",[636,637,638,639,640,641,642,643,644,645,646,647,648],"Epidemiologic Methods","Risk factors","Public Health","Environmental Exposure","Exposome","Dietary Exposure","Diet","Food and Nutrition","Nutritional Status","Metabolomics","Systems biology","Environmental Biomarkers","Inflammation Mediators","2025-08-08",{"date":651,"type":35},"2025-08-11",{"date":653,"type":35},"2022-03-22",{"date":655,"type":21},"2030-03-22",{"name":657,"class":42},"University Hospital, Bordeaux",{"id":659,"slug":4,"hasResults":11,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":11,"sex":17,"minAge":664,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":666,"conditions":667,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":159},"100562683","NCT06606353","Talk-to-Jo\" Intelligent Digital Health Companion, Neurocognitive Disorders and Dyads","Talk-to-Jo\" Intelligent Digital Health Companion, Neurocognitive Disorders and Dyads: a Qualitative Study","1. Person living with an neurocognitive disorder (NCD):\n\n   1. Inclusion criteria:\n\n      * Be 65 years old or older.\n      * Have an NCD, whether minor or major, in a mild to moderate stage, diagnosed within the past year.\n      * Be receiving care for an NCD at the outpatient clinic of the Montreal Geriatric University Institute.\n      * Have a caregiver.\n      * Live in a personal residence or in a non-medicalized senior residence.\n      * Be able to understand spoken and written French. The \"Talk-to-Jo\" avatar has only been developed in the French language and can only communicate and understand French.\n   2. Exclusion criteria:\n\n      * Inability to provide informed consent for participation in the study.\n      * Participating in a concurrent experimental clinical study, to avoid interference with our study.\n      * Living in a Long-Term Care Facility or in a medicalized section of an non-medicalized senior residence.\n      * Inability to understand spoken and written French.\n      * Having a moderate to severe visual or auditory impairment. The criterion for assessing hearing impairment will be the person's ability to understand and participate in a phone conversation. Individuals with impairments who use hearing aids or glasses to compensate for the impairments may be included.\n2. Caregiver\n\n   1. Inclusion criteria:\n\n      * Be a caregiver for a person living with an NCD (regardless of the relationship: spouse, child, friend, neighbor, family member).\n      * Be able to understand spoken and written French.\n   2. Exclusion criteria:\n\n      * Have an NCD.\n      * Inability to understand spoken and written French.\n      * Participating in a concurrent experimental clinical study, to avoid interference with our study.\n      * Having a moderate to severe visual or auditory impairment. The criterion for assessing hearing impairment will be the person's ability to understand and participate in a phone conversation. Individuals with impairments who use hearing aids or glasses to compensate for the impairments may be included.","65 Years",{"count":596,"type":21},"By 2050, one in six people in the world will be over 65, leading to an increase in the number of people with neurocognitive disorders (NCD), such as Alzheimer's disease. The number of cases will rise from 57 million to 153 million by 2050. This presents challenges for healthcare systems, as NCDs affect not only mental health but also the physical health, psychological well-being, and social relationships of patients, as well as their caregivers (PCA).\n\nIn Quebec, primary care is often inadequate for people living with NCDs due to delays in accessing resources, incomplete coverage of needs, and the COVID-19 pandemic, which has exacerbated these challenges. This situation can lead to a deterioration in patients' health, affecting their quality of life as well as that of their PCAs, while also increasing healthcare costs.\n\nMany elderly people wish to age at home, but cognitive and functional decline complicates this desire. PCAs, generally family members or close friends, play an essential role in the daily support of these individuals. Their role, as defined in the Act to support caregivers in Quebec, includes non-professional and voluntary assistance to improve the quality of life of the person being cared for.\n\nHowever, the support provided by PCAs can lead to significant stress, especially if public services are insufficient. The exhaustion of PCAs is often correlated with the severity of the care recipient's loss of autonomy. This exhaustion impacts the mental and physical health of PCAs, leading to isolation, depression, and anxiety, as well as reduced productivity and an increase in sick leave. It is therefore urgent to find support solutions to prevent PCA burnout.\n\nTelehealth, which involves remote consultations through information and communication technologies (ICT), appears to be a promising solution to improve access to care for people with NCDs, especially in underserved areas. By enabling remote monitoring, telehealth facilitates aging in place while stimulating the remaining capacities of patients, such as responsiveness to sensory stimuli.\n\nArtificial intelligence (AI) is also a promising tool for tracking the health of older adults in real-time, detecting early signs of diseases, and providing personalized recommendations. Virtual assistants or avatars, like \"Talk-to-Jo,\" can interact with patients to reduce their sense of loneliness. However, the effectiveness of these technologies depends on their accessibility and adaptability to the needs of patients, particularly in cases of sensory impairments.\n\n\"Talk-to-Jo\" is a digital avatar designed for older adults with NCDs and their PCAs. It asks questions about memory and depression and provides tailored recommendations to prevent or stabilize detected disorders. A first version of this tool is currently available on a tablet.\n\nWith the growing number of people living with NCDs, it is essential to develop support solutions based on telemedicine and AI. It is important to assess the usability and acceptability of these technologies by patients and their PCAs to ensure their effectiveness.",[668,28],"Caregiver","2025-02-10",{"date":671,"type":35},"2025-02-12",{"date":673,"type":35},"2024-12-12",{"date":675,"type":21},"2026-10",{"name":677,"class":678},"Olivier Beauchet","OTHER_GOV",{"id":680,"slug":4,"hasResults":11,"nctId":681,"briefTitle":682,"officialTitle":683,"acronym":4,"eligibilityCriteria":684,"healthyVolunteers":49,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":685,"targetDuration":4,"studyType":22,"phases":686,"briefSummary":687,"conditions":688,"keywords":689,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":695,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":159},"100548093","NCT06416514","Personalized Interventions Via Health Portraits in Mild Behavioral Impairment","Construction and Empirical Study of Personalized Intervention Based on Health Portrait in Mild Behavioral Impairment","Inclusion Criteria:\n\n* Meet the ISTAART diagnostic criteria for MBI;\n* Age ≥60 years old;\n* No obvious visual or hearing impairment;\n* Have the ability of language communication, can complete the scale assessment.\n\nExclusion Criteria:\n\n* Patients with severe physical diseases and unable to complete cognitive function screening;\n* Patients with other neurological diseases and serious medical diseases that can cause brain dysfunction.",{"count":52,"type":21},[54],"The incidence of MBI and the probability of progression to dementia are high. Early detection and intervention have important clinical significance to reduce the occurrence of dementia, delay the progression of dementia and promote healthy aging to active aging. The occurrence and development of NPS in MBI patients may be related to genetic and degenerative changes in the central nervous system. The evaluation of MBI patients is mainly based on neuropsychological tests, including NPS and cognitive function assessment. Landmark model is an effective tool for dynamic risk prediction of the progress of MBI. It can make dynamic prediction at different time points according to various existing measurement indicators of an individual and calculate the individual prediction probability, which is one of the best models for studying the outcome of disease at present. The Landmark model is applied to the elderly MBI population to study the influencing factors of normal aging, MBI and dementia and the probability of metastasis, which is a beneficial attempt to further advance the defense line of dementia. Personalized non-drug intervention is the preferred treatment for MBI, which mainly includes cognitive\u002Femotional intervention, sensory stimulation, exercise therapy, etc. Currently, it is recommended to adopt diversified strategies to implement individualized precision treatment programs for patients. The hierarchical and classified health management of elderly MBI patients combined with health portrait technology is helpful to improve management efficiency and better meet the needs of personalized health management for the elderly.",[28],[690,691,692,693,694],"Mild behavioral impairment","Older adults","Personalized intervention","Health portrait","Neuropsychiatric symptoms","2024-07-17",{"date":697,"type":35},"2024-07-18",{"date":699,"type":35},"2024-06-25",{"date":701,"type":21},"2027-12-30",{"name":703,"class":42},"Fujian Provincial Hospital",{"id":705,"slug":4,"hasResults":11,"nctId":706,"briefTitle":707,"officialTitle":708,"acronym":709,"eligibilityCriteria":710,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":711,"targetDuration":4,"studyType":22,"phases":713,"briefSummary":714,"conditions":715,"keywords":717,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":725,"completionDateStruct":727,"leadSponsor":729,"locationsCount":159},"100425889","NCT04825847","Neurocognitive Disorders After Major Surgery in Elderly","Effect of Electroencephalography-guided Anesthesia on Neurocognitive Disorders in Elderly Patients Undergoing Major Non-cardiac Surgery: a Randomized Clinical Trial","POEGEA","Inclusion Criteria:\n\n* Patients 70 years of age or older,\n* Major gynecologic, abdominal, urologic, thoracic or orthopedic surgery via laparoscopy or laparotomy under general anesthesia - with or without concomitant use of regional or neuraxial anesthesia -,\n* Expected anesthesia time of more than 60 minutes,\n* Seen for assessment by internal medicine and\u002For anesthesiology at the preoperative clinic (CIEPC)\n\nExclusion Criteria:\n\n* Known diagnosis of dementia or other neurological, psychiatric, developmental or medical condition that resulted in documented severe cognitive impairment,\n* Emergency surgery,\n* Significant auditory or visual impairment that precludes participation in cognitive testing,\n* Known allergy or intolerance or other medical condition that precludes the use of prescribed general anesthesia protocol for this study,\n* Inability to communicate in French or English.",{"count":712,"type":21},314,[54],"The objective of the study is to investigate, in patients aged 70 years and over undergoing major non-cardiac surgery, the effect of electroencephalic (EEG)-guided anesthesia on postoperative neurocognitive disorders when controlling for intraoperative nociception, personalized blood pressure targets and using full information provided by the processed EEG monitor (including burst suppression ratio, density spectral array and raw EEG waveform).\n\nThis prospective, randomized, controlled trial will be conducted in a single Canadian university hospital. Patients aged 70 years and over, undergoing elective major non-cardiac surgery will be included. The administration of sevoflurane will be adjusted to maintain a BIS value between 40 and 60, a suppression Ratio at 0%, a direct EEG display without any suppression time and a spectrogram with most of the EEG wave frequency within the alpha, theta and delta frequencies in the EEG-guided group. In the control group sevoflurane will be administered to achieve an age-adjusted minimum alveolar concentration of \\[0.8-1.2\\]. A nociception monitor will guide intraoperative opioids' infusion and individual blood pressure targets will be personalized in both groups. The primary endpoint is the incidence of neurocognitive disorder (NCD) at postoperative day 1 evaluated by the Montréal Cognitive Assessment. Secondary endpoints include the incidence of postoperative neurocognitive disorder at different timepoints and the evaluation of cognitive trajectories among EEG-guided and control groups.",[716,28],"Anesthesia",[716,718,719,720,721,722],"Processed EEG Monitor","Neurocognitive disorders","Major surgery","Burst Suppression","MoCA","2024-07-15",{"date":695,"type":35},{"date":726,"type":35},"2021-11-24",{"date":728,"type":21},"2025-08",{"name":730,"class":42},"Ciusss de L'Est de l'Île de Montréal",""]